Event-free survival of patients with distinct ELN prognostic risk scores. Control remission induction therapy versus clofarabine combination treatment. Favorable effect of clofarabine treatment with regard to EFS and OS (OS not shown) in ELN intermediate I risk group. ELN risk 2010 defined as ELN favorable, intermediate I, intermediate II, and adverse as described¹²  and slightly modified for CEBPA biallelic gene mutations as specified in the supplemental Appendix. The favorable effect of the clofarabine regimen on EFS is evident in ELN intermediate I risk group (n = 121 vs 123; EFS, 26% ± 4 vs 40% ± 5, Cox P = .002; OS, 29% ± 5 vs 50% ± 6, P < .001).